


IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Currently Amended)

A compound of structural formula I:



and pharmaceutically acceptable salts thereof, wherein:

R<sup>1</sup> is selected from:

- (1) hydrogen,
- (2) halogen,
- (3) C<sub>1-4</sub>alkyl,
- (4) -CN,
- (5) -C(O)R<sup>7</sup>,
- (6) -OR<sup>d</sup>,
- (7) -NR<sup>5</sup>R<sup>6</sup>, and
- (8) cycloheteroalkyl, pyrrolidinyl.

wherein: alkyl moieties are unsubstituted or substituted with one, two, or three substituents independently selected from R<sup>a</sup>, and ~~cycloheteroalkyl moieties are unsubstituted or substituted with one, two, or three substituents independently selected from R<sup>b</sup>;~~

R<sup>2</sup> is selected from: -NR<sup>5</sup>R<sup>6</sup>, and C<sub>1-6</sub>alkyl, ~~wherein alkyl moieties are unsubstituted or substituted with one, two, or three substituents independently selected from R<sup>a</sup>;~~

R<sup>3</sup> is hydrogen;

R<sup>4</sup> is selected from:

- (1) hydrogen, and
- (2) -CH<sub>2</sub>-R<sup>8</sup>;

R<sup>5</sup> is selected from:

- (1) hydrogen,
- (2) C<sub>1-6</sub>alkyl,
- (3) trifluoromethyl, and
- (4) methylcarbonyl-;

~~wherein the each alkyl moiety is unsubstituted or substituted with one or two R<sup>a</sup> substituents; and~~

R<sup>6</sup> is each selected from:

- (1) hydrogen,
- (2) C<sub>1-6</sub>alkyl,
- (3) phenyl,
- (4) benzyl,
- (5) trifluoromethyl,
- (6) -C(O)-R<sup>c</sup>,
- (7) -CO<sub>2</sub>R<sup>c</sup>, and
- (8) -S(O)<sub>2</sub>CH<sub>3</sub>,

~~wherein each alkyl moiety is unsubstituted or substituted with one or two R<sup>a</sup> substituents; and each phenyl moiety is unsubstituted or substituted with one or two R<sup>b</sup> substituents; or R<sup>5</sup> and R<sup>6</sup> together form =CH-N(CH<sub>3</sub>)<sub>2</sub>;~~

R<sup>7</sup> is selected from:

- (1) hydrogen,
- (2) C<sub>1-3</sub>alkyl,
- (3) -OR<sup>e</sup>, and
- (4) -NR<sup>d</sup>R<sup>e</sup>;

wherein the alkyl moieties are unsubstituted or substituted with one, two, or three substituents independently selected from R<sup>a</sup>;

~~R<sup>7</sup> is selected from:~~

- ~~(1) hydrogen,~~
- ~~(2) C<sub>1-10</sub>alkyl,~~
- ~~(3) C<sub>2-10</sub>alkenyl,~~
- ~~(4) C<sub>2-10</sub>alkynyl,~~
- ~~(5) cycloalkyl,~~
- ~~(6) cycloalkyl C<sub>1-10</sub>alkyl,~~

- ~~(7) —cycloheteroalkyl,~~
- ~~(8) —cycloheteroalkyl-C<sub>1-10</sub>alkyl,~~
- ~~(9) —aryl,~~
- ~~(10) —heteroaryl,~~
- ~~(11) —aryl-C<sub>1-10</sub>alkyl,~~
- ~~(12) —heteroaryl-C<sub>1-10</sub>alkyl,~~
- ~~(13) —OR<sup>e</sup>,~~
- ~~(14) —NR<sup>d</sup>Re,~~
- ~~(15) —NH(C=O)OR<sup>e</sup>, and~~
- ~~(16) —NR<sup>d</sup>SO<sub>2</sub>Re,~~

~~wherein each alkyl, alkenyl, and alkynyl moiety is unsubstituted or substituted with one, two, three or four substituents independently selected from R<sup>a</sup>, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl moiety is unsubstituted or substituted with one, two, three or four substituents independently selected from R<sup>b</sup>;~~

R<sup>8</sup> is selected from:

- (1) hydrogen,
- (2) —(CH<sub>2</sub>)<sub>n</sub>OC(O)CH<sub>3</sub>,
- (3) C<sub>1-6</sub>alkyl,
- (4) C<sub>3-6</sub>cycloalkyl,
- (5) tetrahydrofuranyl,
- (6) phenyl, and
- (7) pyridyl;

wherein the alkyl moieties are unsubstituted or substituted with one substituent independently selected from —OR<sup>e</sup>, and the tetrahydrofuranyl, phenyl and pyridyl moieties are unsubstituted or substituted with one, or two substituents independently selected from OR<sup>e</sup>, halogen, —NR<sup>e</sup>R<sup>f</sup>, —COCH<sub>3</sub>, —C(O)OCH<sub>3</sub>, —CN, and C<sub>1-3</sub> alkyl;

R<sup>8</sup> is selected from:

- (1) —hydrogen,
- (2) —(CH<sub>2</sub>)<sub>n</sub>OC(O)R<sup>e</sup>,
- (3) —C<sub>1-6</sub>alkyl,
- (4) —cycloalkyl,
- (5) —cycloheteroalkyl,
- (6) —phenyl, and

(7) —heteroaryl;

wherein each alkyl moiety is unsubstituted or substituted with one, two, three or four substituents independently selected from  $R^a$ , and each cycloalkyl, cycloheteroalkyl, phenyl and heteroaryl moiety is unsubstituted or substituted with one, or two, or three substituents independently selected from  $R^b$ ;

$Ar^1$  and  $Ar^2$  are each phenyl, either unsubstituted or substituted with one or two substituents independently selected from  $R^b$ ;

each  $R^a$  is independently selected from:  $-OR^e$ , halogen,  $-NR^eR^f$ ,  $-C(O)R^c$ ,  $-CO_2R^c$ ,  $-OC(O)R^c$ ,  $-CN$ ,  $CF_3$ , and  $-OCF_3$ ;

each  $R^a$  is independently selected from:

- (1) — $OR^e$ ;
- (2) — $NR^dS(O)_mR^e$ ;
- (3) — $NO_2$ ;
- (4) —halogen;
- (5) — $S(O)_mR^e$ ;
- (6) — $SR^e$ ;
- (7) — $S(O)_2OR^e$ ;
- (8) — $S(O)_mNR^eR^f$ ;
- (9) — $NR^eR^f$ ;
- (10) — $O(CR^eR^f)_hNR^eR^f$ ;
- (11) — $C(O)R^e$ ;
- (12) — $CO_2R^e$ ;
- (13) — $CO_2(CR^eR^f)_hCONR^eR^f$ ;
- (14) — $OC(O)R^e$ ;
- (15) — $CN$ ;
- (16) — $C(O)NR^eR^f$ ;
- (17) — $NR^dC(O)R^e$ ;
- (18) — $NR^dC(O)OR^e$ ;
- (19) — $NR^dC(O)NR^dR^e$ ;
- (20) — $CR^d(N-OR^e)$ ;
- (21) — $CF_3$ ;
- (22) — $OCF_3$

~~(23) C<sub>3-8</sub>cycloalkyl, and~~

~~(24) cycloheteroalkyl;~~

~~wherein each cycloalkyl and cycloheteroalkyl moiety is unsubstituted or substituted with one, two or three substituents independently selected from R<sup>h</sup>;~~

each R<sup>b</sup> is independently selected from:

(1) R<sup>a</sup>, and

(2) C<sub>1-10</sub>alkyl;

~~(3) cycloalkyl-C<sub>1-4</sub>alkyl;~~

~~(4) cycloheteroalkyl-C<sub>1-4</sub>alkyl;~~

~~(5) aryl;~~

~~(6) aryl-C<sub>1-4</sub>alkyl;~~

~~(7) heteroaryl, and~~

~~(8) heteroaryl-C<sub>1-4</sub>alkyl;~~

~~wherein each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl moiety is unsubstituted or substituted with one, two or three substituents independently selected from R<sup>h</sup>;~~

each R<sup>c</sup> is independently selected from: hydrogen, C<sub>1-6</sub>alkyl, and -NR<sup>d</sup>R<sup>d</sup>; wherein each alkyl moiety may be substituted with one or two substituents selected from R<sup>h</sup> and oxo;

each R<sup>e</sup> is independently selected from:

(1) hydrogen,

(2) C<sub>1-10</sub>alkyl,

(3) C<sub>2-10</sub>alkenyl,

(4) C<sub>2-10</sub>alkynyl,

(5) C<sub>1-8</sub>perfluoroalkyl,

(6) cycloalkyl,

(7) cycloalkyl-C<sub>1-10</sub>alkyl,

(8) cycloheteroalkyl,

(9) cycloheteroalkyl-C<sub>1-10</sub>alkyl,

(10) aryl,

(11) heteroaryl,

(12) aryl-C<sub>1-10</sub>alkyl,

(13) heteroaryl-C<sub>1-10</sub>alkyl, and

~~(14) —NR<sup>d</sup>R<sup>d</sup>,~~

~~wherein each alkyl, cycloalkyl, cycloheteroalkyl, aryl, and heteroaryl moiety is unsubstituted or substituted with one or two R<sup>h</sup> substituents, and each alkyl, cycloalkyl, cycloheteroalkyl may also be substituted on a carbon or sulfur atom with one or two oxo substituents.~~

each R<sup>d</sup> is independently selected from hydrogen, and C<sub>1-6</sub>alkyl;

~~each R<sup>d</sup> is independently selected from hydrogen, C<sub>1-10</sub>alkyl, C<sub>1-10</sub>alkylcarbonyl, aryl, arylcarbonyl, arylsulfonyl, and C<sub>1-10</sub>alkylsulfonyl; wherein each alkyl and aryl moiety is unsubstituted or substituted with one, two or three substituents independently selected from R<sup>h</sup>;~~

R<sup>e</sup> and R<sup>f</sup> are is independently selected from hydrogen and C<sub>1-3</sub>alkyl;

~~R<sup>e</sup> and R<sup>f</sup> are independently selected from hydrogen, C<sub>1-10</sub>alkyl, C<sub>2-10</sub>alkenyl, C<sub>2-10</sub>alkynyl, trifluoromethyl, cycloalkyl, cycloalkyl-C<sub>1-10</sub>alkyl, cycloheteroalkyl, cycloheteroalkyl-C<sub>1-10</sub>alkyl, aryl, heteroaryl, aryl-C<sub>1-10</sub>alkyl, and heteroaryl-C<sub>1-10</sub>alkyl at each occurrence; or when bonded to the same atom, R<sup>e</sup> and R<sup>f</sup> together with the atom to which they are attached form a ring of 5 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen; and each R<sup>e</sup> and R<sup>f</sup> moiety is unsubstituted or substituted on a carbon or nitrogen atom with one, two or three substituents selected from R<sup>h</sup>;~~

each R<sup>h</sup> is independently selected from:

- (1) halogen,
- (2) C<sub>1-10</sub>alkyl,
- ~~(3) C<sub>3-8</sub>cycloalkyl,~~
- ~~(4) cycloheteroalkyl,~~
- ~~(5) aryl,~~
- ~~(6) arylC<sub>1-4</sub>alkyl,~~
- ~~(7) heteroaryl,~~
- ~~(8) heteroarylC<sub>1-4</sub>alkyl,~~
- ~~(9) -OR<sup>i</sup>,~~
- ~~(10) —NR<sup>k</sup>S(O)<sub>m</sub>R<sup>i</sup>,~~

- ~~(11) —S(O)<sub>m</sub>R<sup>i</sup>;~~
- ~~(12) —SR<sup>i</sup>;~~
- ~~(13) —S(O)<sub>2</sub>OR<sup>i</sup>;~~
- ~~(4) (14) —NR<sup>i</sup>R<sup>i</sup>, and~~
- ~~(15) —O(CR<sup>k</sup>R<sup>k</sup>)<sub>n</sub>NR<sup>i</sup>R<sup>i</sup>;~~
- ~~(16) —C(O)R<sup>i</sup>;~~
- ~~(17) —CO<sub>2</sub>R<sup>i</sup>;~~
- ~~(18) —CO<sub>2</sub>(CR<sup>k</sup>R<sup>k</sup>)<sub>n</sub>CONR<sup>i</sup>R<sup>i</sup>;~~
- ~~(5) (19) —OC(O)R<sup>i</sup>;~~
- ~~(20) —CN;~~
- ~~(21) —C(O)NR<sup>i</sup>R<sup>i</sup>;~~
- ~~(22) —NR<sup>k</sup>C(O)R<sup>i</sup>;~~
- ~~(23) —OC(O)NR<sup>i</sup>R<sup>i</sup>;~~
- ~~(24) —NR<sup>k</sup>C(O)OR<sup>i</sup>;~~
- ~~(25) —NR<sup>k</sup>C(O)NR<sup>i</sup>R<sup>i</sup>;~~
- ~~(26) —CF<sub>3</sub>, and~~
- ~~(27) —OCF<sub>3</sub>.~~

each R<sup>i</sup> is independently selected from:

- (1) hydrogen,
- (2) C<sub>1-3</sub>alkyl,
- (3) trifluoromethyl, and
- (4) cyclopropyl;

wherein each alkyl and cycloalkyl moiety is unsubstituted or substituted with one substituent selected from oxo, hydroxy, methoxy, acetoxy, halogen, cyano, and trifluoromethyl;

each R<sup>i</sup> is independently selected from:

- (1) hydrogen,
- (2) C<sub>1</sub>alkyl,
- (3) C<sub>2</sub>alkenyl,
- (4) C<sub>2</sub>alkynyl,
- (5) C<sub>1-6</sub>perfluoroalkyl,
- (6) cycloalkyl,
- (7) cycloalkyl-C<sub>1-6</sub>alkyl;

- (8) ~~cycloheteroalkyl,~~  
(9) ~~cycloheteroalkyl-C<sub>1-6</sub>alkyl,~~  
(10) ~~aryl,~~  
(11) ~~heteroaryl,~~  
(12) ~~aryl-C<sub>1-6</sub>alkyl,~~ and  
(13) ~~heteroaryl-C<sub>1-6</sub>alkyl,~~

wherein each alkyl, cycloalkyl, cycloheteroalkyl, aryl, and heteroaryl is unsubstituted or substituted with one or two substituents selected from hydroxy, methoxy, acetoxy, halogen, cyano, and trifluoromethyl;  
and each alkyl, cycloalkyl, cycloheteroalkyl may be substituted on a carbon or sulfur atom with one or two oxo substituents; and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl may be substituted with methyl;

each R<sup>k</sup> is independently selected from hydrogen, C<sub>1-10</sub>alkyl, C<sub>1-10</sub>alkylcarbonyl, aryl-C<sub>1-3</sub>alkyl, and arylcarbonyl, wherein the alkyl and aryl moieties may be unsubstituted or substituted with one, two or three substituents independently selected from hydroxy, methoxy, acetoxy, halogen, trifluoromethyl, cyano, and aryl may also be substituted with methyl;

m is selected from 1 and 2; and  
n is selected from 1, 2, and 3;

or a pharmaceutically acceptable salt thereof.

Claim 2 (Currently Amended)

The compound according to Claim 1, wherein;

each R<sup>a</sup> is independently selected from: hydroxy, methoxy-, halogen, methylcarbonyl-, -CO<sub>2</sub>R<sup>c</sup>, -OC(O)R<sup>c</sup>, -CN, CF<sub>3</sub>, and -OCF<sub>3</sub>;

each R<sup>d</sup> is independently selected from hydrogen, methyl, and ethyl;

each R<sup>a</sup> is independently selected from:

- (1) ~~OR<sup>e</sup>,~~  
(2) ~~halogen,~~  
(3) ~~NR<sup>e</sup>R<sup>f</sup>,~~  
(4) ~~C(O)R<sup>e</sup>,~~



- (5) —CO<sub>2</sub>R<sup>e</sup>;
- (6) —OC(O)R<sup>e</sup>;
- (7) —CN;
- (8) —CF<sub>3</sub>; and
- (9) —OCF<sub>3</sub>;

each R<sup>b</sup> is independently selected from:

- (1) —R<sup>a</sup>;
- (2) —C<sub>1-6</sub>alkyl;
- (3) —cycloalkylmethyl;
- (4) —cycloheteroalkylmethyl;
- (5) —phenyl;
- (6) —benzyl;
- (7) —pyridyl; and
- (8) —pyridylmethyl;

wherein each cycloalkyl, cycloheteroalkyl, phenyl and pyridyl moiety is unsubstituted or substituted with one, two or three substituents independently selected from R<sup>h</sup>;

each R<sup>c</sup> is independently selected from:

- (1) —hydrogen;
- (2) —C<sub>1-6</sub>alkyl;
- (3) —trifluoromethyl;
- (4) —C<sub>3-7</sub>cycloalkyl;
- (5) —C<sub>3-7</sub>cycloalkyl methyl;
- (6) —cycloheteroalkyl;
- (7) —cycloheteroalkyl methyl;
- (8) —phenyl;
- (9) —pyridyl;
- (10) —benzyl;
- (11) —pyridylmethyl; and
- (12) —NR<sup>d</sup>R<sup>d</sup>;

wherein each alkyl, cycloalkyl, cycloheteroalkyl, aryl, and heteroaryl moiety is may be substituted with one or two R<sup>h</sup> substituents, and each alkyl, cycloalkyl, cycloheteroalkyl may be substituted on a carbon or sulfur atom with one or two exo-substituents;

each  $R^d$  is independently selected from hydrogen, and  $C_{1-6}$ alkyl; wherein the alkyl group may be unsubstituted or substituted with one or two substituents independently selected from  $R^h$ ;

$R^e$  and  $R^f$  are independently selected from hydrogen,  $C_{1-6}$ alkyl, trifluoromethyl, cycloalkyl, cycloalkyl-methyl, cycloheteroalkyl, cycloheteroalkylmethyl, phenyl, pyridyl, benzyl, and pyridylmethyl at each occurrence; or

when bonded to the same atom,  $R^e$  and  $R^f$  together with the atom to which they are attached form a ring of 5 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen; and

each  $R^e$  and  $R^f$  moiety may be unsubstituted or substituted on a carbon or nitrogen atom with one, two or three substituents selected from  $R^h$ ;

each  $R^h$  is independently selected from:

- (1) halogen;
- (2)  $C_{1-3}$ alkyl;
- (3) hydroxy;
- (4) methoxy-; and
- (5)  $-NR^iR^j$ ;

wherein  $R^i$  is selected from hydrogen and methyl; methylcarbonyloxy-;  $-CF_3$ ; and  $-OCF_3$ ;

each  $R^h$  is independently selected from:

- (1) halogen;
- (2)  $C_{1-3}$ alkyl;
- (3) hydroxy;
- (4) methoxy;
- (5)  $-NR^iR^j$ , wherein  $R^i$  is selected from hydrogen and methyl;
- (6) methylcarbonyloxy;
- (7)  $-CF_3$ ; and
- (8)  $-OCF_3$ ;

or a pharmaceutically acceptable salt thereof.

Claim 3 (Currently Amended)

The compound according to Claim 2, wherein

$R^1$  is selected from:

- (1) halogen;
- (2) C<sub>1-3</sub>alkyl, unsubstituted or substituted with hydroxy or methoxy;
- (3) -CN;
- (4) methyloxycarbonyl-;
- (5) methylcarbonyl-;
- (6) isopropyloxycarbonyl-;
- (7) bromomethylcarbonyl-;
- (8) -C(O)NH<sub>2</sub>;
- (9) methoxy-; and
- (10) -NR<sup>5</sup>R<sup>6</sup>, wherein R<sup>5</sup> is methyl and R<sup>6</sup> is C<sub>1-3</sub>alkyl;

R<sup>1</sup> is selected from:

- (1) ~~halogen;~~
- (2) ~~C<sub>1-4</sub>alkyl;~~
- (3) ~~-CN;~~
- (4) ~~-COR<sup>7</sup>;~~
- (5) ~~-OR<sup>d</sup>;~~
- (6) ~~-NR<sup>5</sup>R<sup>6</sup>; and~~
- (7) ~~cycloheteroalkyl;~~

wherein each alkyl moiety is unsubstituted or substituted with one, two, or three substituents independently selected from R<sup>a</sup>, and each cycloheteroalkyl moiety is unsubstituted or substituted with one, two, or three substituents independently selected from R<sup>b</sup>;

each R<sup>i</sup> is independently selected from: hydrogen, and methyl;

and pharmaceutically acceptable salts thereof.

Claim 4 (Currently Amended) The compound according to Claim 2, wherein

R<sup>5</sup> is selected from: hydrogen, methyl, and methylcarbonyl-, and  
R<sup>6</sup> is hydrogen, C<sub>1-3</sub>alkyl, methyl benzyl, -C(=O)R<sup>c</sup>, or -SO<sub>2</sub>CH<sub>3</sub>;

R<sup>7</sup> is selected from:

- (1) C<sub>1-3</sub>alkyl, unsubstituted or substituted with halogen;
- (2) -OR<sup>e</sup>; and

(3)  $\text{-NR}^d\text{R}^e$ ;  
wherein  $\text{R}^d$  is selected from hydrogen and methyl, and  $\text{R}^e$  is selected from hydrogen and  $\text{C}_{1-3}$ alkyl;

$\text{R}^7$  is selected from:

- (1) hydrogen,
- (2)  $\text{C}_{1-6}$ alkyl,
- (3) cycloalkyl,
- (4) cycloheteroalkyl,
- (5) aryl,
- (6) heteroaryl,
- (7) heteroaryl- $\text{C}_{1-10}$ alkyl,
- (8)  $\text{OR}^e$ ,
- (9)  $\text{NR}^d\text{R}^e$ , and
- (10)  $\text{NH}(\text{C}=\text{O})\text{OR}^e$ ,

wherein each alkyl moiety is unsubstituted or substituted with one, two, or three substituents independently selected from  $\text{R}^a$ , and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl moiety is unsubstituted or substituted with an  $\text{R}^b$  substituent;

and pharmaceutically acceptable salts thereof.

Claim 5 (Currently Amended)

The compound according to Claim 4, wherein:

$\text{R}^1$  is selected from:

- (1)  $\text{-C(O)CH}_3$ ,
- (2)  $\text{-CH(OH)CH}_3$ ,
- (3)  $\text{-CH}_3$ ,
- (4)  $\text{-CH}_2\text{CH}_3$ ,
- (5)  $\text{-CH(CH}_3)_2$ ,
- (6)  $\text{-CH(OCH}_3)(\text{CH}_3)$ ,
- (7)  $\text{-C(O)-OCH}_3$ ,
- (8)  $\text{-C(O)OCH(CH}_3)_2$ ,
- (9)  $\text{-CN}$ ,  $\text{-C(O)NH}_2$ ,
- (10)  $\text{-C(O)N(CH}_3)_2$ , -
- (11)  $\text{Cl}$ .

- (12) -N(CH<sub>3</sub>)<sub>2</sub>,
- (13) -N(CH<sub>3</sub>)(CH(CH<sub>3</sub>)<sub>2</sub>), and
- (14) pyrrolidinyl;

R<sup>1</sup> is selected from:

- (1) —halogen;
- (2) —C<sub>1-3</sub>alkyl, unsubstituted or substituted with hydroxy or methoxy;
- (3) —CN;
- (4) —methyloxycarbonyl;
- (5) —methylcarbonyl;
- (6) —isopropyloxycarbonyl;
- (7) —bromomethylcarbonyl;
- (8) —C(O)NH<sub>2</sub>;
- (9) —methoxy;
- (10) —NR<sup>5</sup>R<sup>6</sup>, wherein R<sup>5</sup> is methyl and R<sup>6</sup> is C<sub>1-3</sub>alkyl, or R<sup>5</sup> and R<sup>6</sup>, together with the nitrogen to which they are attached, form a 5-membered cycloheteroalkyl ring, and
- (11) —cycloheteroalkyl;

R<sup>2</sup> is or C<sub>1-6</sub>alkyl or NR<sup>5</sup>R<sup>6</sup>, wherein R<sup>5</sup> is selected from: hydrogen, methyl, and methylcarbonyl-, and R<sup>6</sup> is selected from, hydrogen, methyl benzyl, -C(=O)R<sup>c</sup>, and -SO<sub>2</sub>CH<sub>3</sub>;

R<sup>4</sup> is selected from:

- (1) —hydrogen;
- (2) —C<sub>1-5</sub>alkyl;
- (3) —benzyl;
- (4) —pyridylmethyl;
- (5) —cycloalkyl-methyl;
- (6) —cycloheteroalkyl-methyl;

wherein each alkyl moiety is unsubstituted or substituted with one, two, three or four substituents independently selected from R<sup>a</sup>; and each cycloalkyl, cycloheteroalkyl, phenyl and pyridyl moiety is unsubstituted or substituted with one, two, or three substituents independently selected from R<sup>b</sup>;


R<sup>5</sup> is selected from: hydrogen, methyl, and methylcarbonyl-, and

R<sup>6</sup> is hydrogen, C<sub>1-3</sub>alkyl, methyl benzyl, or -C(=O)R<sup>c</sup>;

Ar<sup>1</sup> is phenyl, substituted with one or two substituents independently selected from halogen and methyl;

Ar<sup>2</sup> is phenyl, either unsubstituted or substituted with one or two halogen substituents;  
or a pharmaceutically acceptable salt thereof.

Claim 6 (Previously Presented)      The compound according to Claim 1, of structural formula IA:



wherein R<sup>1</sup>, R<sup>2</sup>, and R<sup>4</sup> are as defined in Claim 1;  
and pharmaceutically acceptable salts thereof.

Claim 7 (Previously Presented)      A compound selected from:

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

3-acetyl-4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2(1*H*)-one;

*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(1-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2(1*H*)-one;

*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-ethyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

3-acetyl-4-(benzylamino)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2(1*H*)-one;

3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-4-(dimethylamino)-1-methyl-1,8-naphthyridin-2(1*H*)-one;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N,N*-dimethylurea;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N*-methyleacetamide;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-2-methoxyacetamide;

*N*-[3-acetyl-1-benzyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-6-(4-chlorophenyl)-1-(cyclopropylmethyl)-7-(2,4-dichlorophenyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-1-butyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2-methoxyethyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1-(tetrahydrofuran-2-ylmethyl)-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

2-[[3-acetyl-4-(acetylamino)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1,8-naphthyridin-1(2*H*)-yl]methyl}pyridinium trifluoroacetate;

3-[[3-acetyl-4-(acetylamino)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1,8-naphthyridin-1(2*H*)-yl]methyl}pyridinium trifluoroacetate;

2-[3-acetyl-4-(acetylamino)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1,8-naphthyridin-1(2*H*)-yl]ethyl acetate;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2,4-dimethoxybenzyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

4-[[3-acetyl-4-(acetylamino)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1,8-naphthyridin-1(2*H*)-yl]methyl}pyridinium trifluoroacetate;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1-propyl-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-7-(2-chlorophenyl)-6-(4-chlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-7-(2-chlorophenyl)-6-(4-chlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-(1-(2,4-dimethoxybenzyl)-3-acetyl-7-(2,4-dichlorophenyl)-6-(4-chlorophenyl)-1,2-dihydro-2-oxo-1,8-naphthyridin-4-yl)-*N*-acetylacetamide;

*N*-(1-(2,4-dimethoxybenzyl)-7-(2,4-dichlorophenyl)-6-(4-chlorophenyl)-1,2-dihydro-2-oxo-1,8-naphthyridin-4-yl)-*N*-acetylacetamide;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2-hydroxyethyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]methanesulfonamide;

2-{[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]amino}-2-oxoethyl acetate;

*N*-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-2-hydroxyacetamide;

*N*-[3-acetyl-7-(2,4-dichlorophenyl)-1-methyl-6-(4-methylphenyl)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[3-acetyl-7-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1,3-dimethyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]propanamide;

*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]butanamide;

4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1,3-dimethyl-1,8-naphthyridin-2(1*H*)-one;

*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1,3-dimethyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-1,8-naphthyridin-2(1*H*)-one;

*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N*-methylacetamide;

2-{[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]amino}-2-oxoethyl acetate;

2-chloro-*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;

*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-2-methoxyacetamide;



*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N*<sup>9</sup>-ethylurea;  
*N*-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-2-hydroxyacetamide;  
*N*<sup>1</sup>-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N*<sup>2</sup>,*N*<sup>2</sup>-dimethylglycinamide;  
*N*<sup>1</sup>-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N*<sup>2</sup>-methylglycinamide;  
*N*<sup>1</sup>-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]glycinamide;  
4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-methyl-1,8-naphthyridin-2(1*H*)-one;  
4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-isopropyl-1-methyl-1,8-naphthyridin-2(1*H*)-one;  
4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methyl-1-propyl-1,8-naphthyridin-2(1*H*)-one;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-isopropyl-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methyl-2-oxo-1-propyl-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(1-methoxyethyl)-1-methyl-1,8-naphthyridin-2(1*H*)-one;  
4-amino-3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-1,8-naphthyridin-2(1*H*)-one;  
*N*-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
4-amino-3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2(1*H*)-one;  
*N*-acetyl-*N*-(3-chloro-7-(2,4-dichlorophenyl)-6-(4-chlorophenyl)-1,2-dihydro-1-isobutyl-2-oxo-1,8-naphthyridin-4-yl)acetamide;  
*N*-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
*N*<sup>1</sup>-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N*<sup>2</sup>,*N*<sup>2</sup>-dimethylglycinamide;

2-([3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]amino)-2-oxoethyl acetate;  
*N*-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-2-hydroxyacetamide;  
*N*-acetyl-*N*-(3-chloro-7-(2-chlorophenyl)-6-(4-chlorophenyl)-1,2-dihydro-1-isobutyl-2-oxo-1,8-naphthyridin-4-yl)acetamide;  
*N*-[3-chloro-7-(2-chlorophenyl)-6-(4-chlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
*N*-[3-chloro-7-(2-chloro-4-fluorophenyl)-6-(4-chlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(dimethylamino)-1-methyl-1,8-naphthyridin-2(1*H*)-one;  
*N*-acetyl-*N*-(7-(2,4-dichlorophenyl)-6-(4-chlorophenyl)-3-(dimethylamino)-1,2-dihydro-1-methyl-2-oxo-1,8-naphthyridin-4-yl)acetamide;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(dimethylamino)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-[isopropyl(methyl)amino]-1-methyl-1,8-naphthyridin-2(1*H*)-one;  
*N*-(3-(*N*-isopropyl-*N*-methylamino)-7-(2,4-dichlorophenyl)-6-(4-chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-1,8-naphthyridin-4-yl)-*N*-acetylacetamide;  
*N*-{6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-[isopropyl(methyl)amino]-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl}acetamide;  
*N*-acetyl-*N*-(7-(2,4-dichlorophenyl)-6-(4-chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-3-(pyrrolidin-1-yl)-1,8-naphthyridin-4-yl)acetamide;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-3-pyrrolidin-1-yl-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methoxy-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
*N*-acetyl-*N*-(7-(2,4-dichlorophenyl)-6-(4-chlorophenyl)-1,2-dihydro-1-isobutyl-3-methoxy-2-oxo-1,8-naphthyridin-4-yl)acetamide;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methoxy-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
*N*'-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N,N*-dimethylimidoforamide;

*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N,N*-dimethylimidoforamide;  
*N*-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N,N*-dimethylimidoforamide;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-isobutyl-3-methoxy-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-*N,N*-dimethylimidoforamide;  
*N*-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(1-methoxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-isopropyl-1-methyl-4-(methylamino)-1,8-naphthyridin-2(1*H*)-one;  
methyl 4-(acetylamino)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate;  
methyl 4-(*N*-acetylacetamido)-7-(2,4-dichlorophenyl)-6-(4-chlorophenyl)-1,2-dihydro-1-methyl-2-oxo-1,8-naphthyridine-3-carboxylate;  
isopropyl 4-(acetylamino)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate;  
ethyl 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate;  
4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide;  
4-(acetylamino)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-*N,N*,1-trimethyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide;  
4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carbonitrile;  
*N*-[6-(4-chlorophenyl)-3-cyano-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide;  
and pharmaceutically acceptable salts thereof.

Claims 8 – 12 (canceled)

Claim 13 (Original)     A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

Claims 14-17 (canceled)